.Merck trumps incomes assumptions, rears sales outlook on powerful demand for top drugs like Keytruda CNBCMerck & Co. (MRK United States) Defeats Revenue Projections as Keytruda Sales Growth BloombergMerck Supply: Pharma Titan Posts Sturdy End Results, Yet Overview Tumbles Short Investor's Business DailyMerck Announces Second-Quarter 2024 Financial Results Yahoo FinanceMerck defeats revenue as well as purchases expectations in the middle of Keytruda advantage, yet delivers blended full-year outlook MarketWatch.